NCT00404001已完成2 期
A Phase 2, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Range-Finding Study of the Safety and Efficacy of Orally Administered MD-0727 in Patients With Primary Hypercholesterolemia
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 150
- 试验地点
- 20
- 主要终点
- Low density lipoprotein cholesterol (LDL-C)
研究概览
简要总结
The primary objectives of this study are to evaluate the safety of MD-0727 in patients with primary hypercholesterolemia and to determine the low density lipoprotein cholesterol (LDL-C) lowering effect and dose-response of MD-0727 in patients with primary hypercholesterolemia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient is male or non-pregnant, non-breastfeeding female, at least 18 years of age
- •Patient must agree to use contraception and/or birth control if sexually active
- •Patient may not be on lipid-lowering therapies at least 6 weeks prior to study and must have a fasting LDL-C 130 mg/dl or greater at Screening
- •Patient must have an average of two fasting LDL-C measures greater than/equal to 130 mg/dl but less than/equal to 210 mg/dl with a difference in the two measures less than/equal to 15%. Patient may not have a fasting serum triglyceride less than 300 mg/dl during Pre-treatment Period
- •Patient's BMI must be greater than/equal to 18.5 but less than 35.0 at Screening
- •Patient must complete a physical exam, 12-lead ECG, and other laboratory tests (including pregnancy test) with no clinically-significant findings prior to the first dose of study medication
- •Patient agrees to comply with the TLC diet
- •Patient completes a 6-week washout of previous lipid-lowering medication including over-the-counter products
排除标准
- •Patient has a medical condition that is prohibited per protocol or a condition that the Investigator believes may limit the patient's ability to participate in the study
- •Patient has a TSH level >1.5 X the upper limit of normal
- •Patient has history of cardiovascular or coronary artery disease, uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins, or patient has history of NYHA Class III or IV congestive heart failure
- •Patient is diabetic or presents with fasting blood glucose greater than/equal to 126 mg/dl at any time prior to randomization
- •Patient has uncontrolled hypertension with a systolic blood pressure greater than/equal to 180 mm Hg or diastolic blood pressure greater than/equal to 110 mmg Hg at two study visits prior to the first dose of study medication
- •Patient has a 10-year CHD risk of > 20%
- •Patient has ALT or AST > 1.5 X the upper limit of normal prior to randomization
- •Patient has a history of alcohol or drug abuse within 12 months of Screening
- •Patient has used a prohibited medication (per protocol) during the 14-day Pre-treatment Visit
结局指标
主要结局
Low density lipoprotein cholesterol (LDL-C)
次要结局
- Total cholesterol
研究者
研究点 (20)
Loading locations...
相似试验
已完成
2 期
A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne VulgarisAcne VulgarisNCT00666900Dow Pharmaceutical Sciences366
已完成
2 期
A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia GravisGeneralized Myasthenia GravisNCT03772587Momenta Pharmaceuticals, Inc.68
已完成
1 期
Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Refractory Multiple MyelomaRelapsed and/or Refractory Multiple MyelomaNCT00882063Piramal Enterprises Limited19
已完成
2 期
Safety and Efficacy of S-707106 in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control With Metformin TherapyType 2 Diabetes MellitusNCT01240759Shionogi218
已完成
2 期
Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema AttacksHereditary Angioedema (HAE)NCT01756157Shire47